NRx Pharmaceuticals (NASDAQ: NRXP) announced that its subsidiary HOPE Therapeutics has opened a new clinic in Palm Beach, Florida, focused on treating depression and post-traumatic stress disorder through an interventional psychiatry approach that includes ketamine and other neuroplastic drugs, transcranial magnetic stimulation (TMS), hyperbaric oxygen therapy and physician-led psychotherapy. The facility expands HOPE’s growing network of clinics and builds on a nationwide partnership with neurocare AG to bring non-invasive neuroplastic therapies to patients. Peer-reviewed publications cited by the company report an 87% clinical response rate in treatment-resistant depression using short-term treatment protocols, while pilot programs incorporating hyperbaric oxygen therapy have shown a 90% return-to-function rate among patients with depression and PTSD.
NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://nnw.fm/NRXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer